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Chlamydia trachomatis control eﬀorts that enhance detection and treatment of infected women may paradoxically increase
susceptibility of the population to infection. Conversely, these surveillance programs lower incidences of adverse sequelae elicited
by genital tract infection (e.g., pelvic inﬂammatory disease and ectopic pregnancy), suggesting enhanced identiﬁcation and
eradication of C. trachomatis simultaneously reduces pathogen-induced upper genital tract damage and abrogates formation of
protective immune responses. In this paper, we detail ﬁndings from C. trachomatis infection control programs that increase our
understanding of chlamydial immunoepidemiology and discuss their implications for prophylactic vaccine design.
1.Introduction
An estimated 90 million individuals sexually acquire
Chlamydiatrachomatisinfectioneachyear(including45mil-
lion in Asia, 15 million in Africa, and 4 million in the United
States [1]), and in all these geographic regions the highest
prevalences of chlamydial genital tract infection are found
among adolescents and young adults [2]. Although C. tra-
chomatis is a common cause of male nongonococcal urethri-
tis [3], female genital tract infections represent more signif-
icant threats to reproductive health. Morbidities associated
withC. trachomatis genital tract infections in women include
pelvicinﬂammatorydisease(PID)anditssequelaeofchronic
pelvic pain, ectopic pregnancy, and tubal infertility [4].
2. Shortcomings and Beneﬁts of
Infection Control Programs
During the past 25 years, many areas in Europe and North
America implemented infection control programs to reduce
sexual transmission of C. trachomatis [5]. These programs
typicallyrelieduponwidespreadscreeningandprompttreat-
ment of asymptomatic individuals as a conduit for decreased
population infectivity [6–8]. Applying these principles, one
regional United States program reduced C. trachomatis
prevalence60% amongyoung womenduring theﬁrst9years
ofitsexistence[9].However,similarscreeningandtreatment
of young women in this region during the succeeding 7 years
was associated with a 46% increase in chlamydial positivity
[10]. This scenario was repeated in British Columbia—after
introduction of a C. trachomatis infection control program
case rates fell from 216 to 104 cases per 100000 individuals
butthensteadilyclimbedto193casesper100000individuals
[11]. In fact, nearly all countries implementing large-scale
chlamydial control programs have reported increased case
report numbers despite ongoing control eﬀorts [12–14],
suggesting expanded earlier treatment may enhance popula-
tion susceptibility to C. trachomatis infection. Although the
higher prevalences of C. trachomatis seen in areas with active
surveillancemayhavebeensequelaetoincreasedscreeningof
higher risk women or increased use of more sensitive diag-
nostic tests, at least in 1 such surveillance program higher
prevalence appeared to reﬂect actual increases in chlamydial
positivity [15]. Providing stronger support for the supposi-
tion that C. trachomatis infection control programs increase
population susceptibility to infection, British Columbia saw2 Infectious Diseases in Obstetrics and Gynecology
reinfection rates rise from 9.7 to 53.2 cases per 100,000 indi-
viduals in the midst of widespread control eﬀorts [11, 15].
Concurrent with higher incidences of reinfection, how-
ever, C. trachomatis control programs have reduced geni-
tal tract complications elicited by infection. For example,
concomitant with steady increases in C. trachomatis case
numbers, health oﬃcials in San Francisco County, Calif,
observed dramatic decreases in PID and ectopic pregnancy
cases [16]. Earlier diagnosis and treatment of genital tract
chlamydial infections was also associated with sharp reduc-
tions in ectopic pregnancy rates in Norway and Sweden
[17, 18]. Despite the substantially increased rates of C.
trachomatis infection documented in British Columbia [11],
surveillance data demonstrated robust decreases in annual
case numbers and rates of PID, ectopic pregnancy, and tubal
factor infertility [19]. Taken together, these data imply that
enhanced detection and earlier treatment of infected women
achieved upon implementation of C. trachomatis infection
control programs may have been responsible for reduced
incidencesoftheadverseoutcomesassociatedwithascension
of this pathogen into the upper genital tract. These data
further imply that persistent C. trachomatis infection, not
simply acquisition or reinfection, may be the scenario most
likelyresponsiblefordevelopmentofPID,ectopicpregnancy,
and tubal factor infertility.
3.C. trachomatis Control Programs and
the ArrestedImmunityHypothesis
Seminal investigations performed in British Columbia
allowedBrunhametal.toﬁrstpositthatC.trachomatisinfec-
tion control programs increase population susceptibility to
reinfection [11]. Their “altered immunity” hypothesis states
that development of protective immune responses against C.
trachomatis is abrogated by earlier detection and treatment
of infected individuals and further argues this interrupted
development of protective immunity increases the likeli-
hood of reinfection. Evidence supporting this proposed
linkage between expanded earlier treatment and increased
population susceptibility to infection has been provided by
both experimental and clinical investigations. Compared to
untreated mice, humoral immune responses were impaired
in the vaginas of mice administered doxycycline within the
ﬁrst 10 days of primary intravaginal chlamydial infection.
Moreover, these same antibiotic-treated mice were also less
protected from chlamydial reinfection [20]. Taken together,
these data suggest that accelerated eradication of chlamydia
from the genital tract that was mediated by doxycycline
therapy may have hampered the development of protective
immune responses.
The durability of C. trachomatis infection among many
women not receiving antichlamydial antibiotics implies pro-
tracted courses of infection may be needed for development
of sterilizing immunity, while providing further support for
thevalidity of thealteredimmunity hypothesis. Forexample,
an annual clearance rate of 45% among asymptomatic
Dutch women not receiving antimicrobial therapy suggested
sterilizing immunity is often not achieved during the ﬁrst
year of a chlamydial genital tract infection [21]. A similar
rate of clearance was seen in Colombia where 54% (44/82)
of women not receiving antichlamydial antibiotics cleared
asymptomatic genital tract infection during the ﬁrst year
after initial diagnosis; however C. trachomatis infection
persisted in only 6% of this cohort after 4 years of followup
[22]. These results indicate the development of sterilizing
immunity against genital tract chlamydial infection is most
oftenmeasuredinmonthsoryears,whilelong-termpresence
of the organism in the absence of overt inﬂammatory symp-
tomshighlights thehighly successfulparasitic relationship C.
trachomatishasachievedwithitshumanhosts.Inadditionto
these natural history studies, clinical data in support of the
altered immune hypothesis was generated upon completion
of a C.t r a c h o m a t i sseroprevalence study enrolling 8000
pregnant Finnish women. During the same period of time
in this country in which dramatic increases in the frequency
of genital tract chlamydial infection were observed [23], this
study reported a 51% decrease in the prevalence of positive
serum IgG antibody titers against C. trachomatis major outer
membrane protein (MOMP) among women less than 23
years of age and a 65% decrease in positive titers among 23–
28-year-old women [24]. These ﬁndings may indicate that in
somewomen chlamydialMOMP-speciﬁchumoral responses
are transitory or, conversely, that humoral responses against
C. trachomatis are slow to develop and that earlier identiﬁ-
cation and treatment of infection impeded the development
of humoral immunity. Although more speculative, it is also
possible that decreasing seroprevalence of C. trachomatis in
Finland contributed to increased population susceptibility
to reinfection. This latter clinical scenario is consistent with
experimental data demonstrating that chlamydial-speciﬁc
antibodies were integral for protection of female mice from
genital tract reinfection [25]. Further clinical investigation,
however, will be needed to determine the strength of the
associations between enhanced detection and treatment,
impaired humoral immune responses, and increases in
susceptibility to C. trachomatis genital tract reinfection.
4. Implications for C. trachomatis
Vaccine Development
Widespread C. trachomatis infection control programs
reduce incidences of PID and its adverse sequelae [19, 26],
but are associated with increased population susceptibility
to infection. These seemingly contradictory observations
interestingly help illuminate the immunoepidemiology of
C. trachomatis infection. Although some conclusions that
we draw from these epidemiological investigations remain
conjectural, increased population susceptibility to chlamy-
dial infection seen concomitantly with decreases in genital
tract complications of infection indicates the following: (1)
this obligate intracellular pathogen is weakly antigenic; (2)
the organism requires persistent infection to elicit upper
genital tract damage; (3) primary infection is associated with
host immune responses that are suboptimal for immediate
pathogen clearance but unlikely to damage vital upper
genital tract architecture and/or this organism employsInfectious Diseases in Obstetrics and Gynecology 3
immunoevasion strategies that promote establishment of
asymptomatic but persistent infection.
Consistent with the notion of low antigenicity, C.
trachomatis infections of the female genital tract often
remain asymptomatic. Cell walls of C. trachomatis, like other
Gram-negative bacteria, contain lipopolysaccharide (LPS),
a molecule that stimulates multiple responses in infected
tissue including increased secretion of pro-inﬂammatory
cytokines, macrophage activation, and increased expression
of endothelial leukocyte adhesion molecules. Ex vivo assays
show that LPS is primarily responsible for the increased
production of tumor necrosis factor (TNF) elicited by C.
trachomatis elementary bodies, even though chlamydia LPS
is 100-fold less potent for the production of this key pro-
inﬂammatory cytokine than the LPS isolated from Neisseria
species [27]. Therefore, epidemiological data suggesting that
the presence of persistent genital tract infection promotes
chlamydial disease expression is consistent with this ability
of C. trachomatis to elicit less robust inﬂammatory responses
[28]. In other words, pelvic inﬂammatory disease, fallopian
tube scarring, and tubal infertility may more frequently
result from the presence of chronic, albeit mild inﬂamma-
tion. Although persistent infection may be responsible for
increasedchlamydialdiseaseexpression,thespeciﬁcimmune
responses that evoke this upper genital tract damage remain
unknown. Mouse and nonhuman primate studies suggest
IFN-γ-producing CD4+ T cells are needed for clearance of
chlamydialinfections,andthegenerationofappropriatetype
1 immunity is often considered to be an integral component
of any vaccine conferring protection against chlamydial
disease expression [29]. On the other hand, increased IFN-
γ production, in conjunction with other type 1 responses,
may promote immunopathological responses and increase
the likelihood of fallopian tube scarring and tubal factor
infertility. Since genital tract C. trachomatis infections in
nature are weakly antigenic, it is at least a theoretical concern
that chlamydial vaccines that confer protection via genera-
tion of robust, more durable memory T cell responses could
also elicit immunopathological damage if repetitive bouts of
inﬂammation were elicited upon subsequent exposures to
the organism.
C. trachomatis is known to have evolved exclusively as a
human pathogen and fact which may explain why infection
usually occurs in the absence of overt inﬂammation. Strate-
gies developed by this intracellular pathogen to avoid host
detection or clearanceinclude replication within membrane-
bound inclusions [30], suppression of class I and II major
histocompatibility complex molecule expression by infected
cells [31], and its ability to capture indole to escape IFN-
γ-mediated tryptophan starvation [32]. A high-frequency
asymptomatic C. trachomatis infection, on the other hand,
may be the consequence of host responses that evolved to
minimize collateral damage to delicate upper genital tract
structures. In support of this hypothesis, we recently saw
that C. trachomatis genital tract infection was associated with
increased numbers of endometrial CD4+ T cells, B cells, and
plasma cells [33], suggesting there is a predilection for C.
trachomatis infection to polarize endometrial inﬂammation
towardtype 2 immunity. Although type1 immune responses
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Figure 1: Schema summarizing outcomes associated with Chlamy-
dia trachomatis genital tract infection control programs. These
outcomes include increased number of chlamydial cases, increased
rates of chlamydial reinfection, decreased detection of chlamydial-
speciﬁc serum antibodies, and decreased rates of pelvic inﬂam-
matory disease, ectopic pregnancy, and tubal factor infertility.
Although no causality between these observed outcomes has been
established, chlamydial vaccine development will require better
delineation of the linkage between enhanced early treatment and
diminished antichlamydial humoral immunity, increased suscep-
tibility to infection, and lower incidences of adverse reproductive
tract sequelae.
are capable of clearing C. trachomatis, type 2 responses
may have been selected as a safer alternative to more
damaging type 1 responses in the upper genital tract [34].
Whether type 2 endometrial inﬂammation is associated
with enhanced or impaired chlamydial clearance or higher
or lower chances of immunopathological tissue damage
remains unknown, but resolution of these uncertainties is
essential for proper vaccine development. The reported link-
age between enhanced early detection, decreased chlamydia-
speciﬁc antibody prevalence, and increased chlamydial rein-
fection rates does not establish causality between impaired
humoral immune responses and increased susceptibility to
infection, but does provide the impetus for more complete
understanding of the immune responses that may impact
chlamydial vaccine eﬃcacy.
In conclusion, this brief paper summarized the ﬁndings
fromC.trachomatisinfectioncontrolprogramsthatalterour
understanding of the immunoepidemiology of chlamydial
genital tract infection (Figure 1). Although observations
from these programs suggest increased duration of infection
is a risk factor for the development of PID, understanding
of the speciﬁc host genetic variations and immune responses
that promote genital tract damage awaits further investi-
gation. Additional work is also needed to better inform
chlamydial vaccine development, as more comprehensive4 Infectious Diseases in Obstetrics and Gynecology
understanding of the immune responses that protect against
C. trachomatis acquisition and reinfection and prevent or
elicit PID development must be achieved before clinical
vaccination trials can be safely initiated.
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